Multiple Myeloma Research and TreatmentsBone health and treatmentsPeptidase Inhibition and AnalysisBone Metabolism and DiseasesBone and Joint Diseases
Publications
233
Citations
11,921
Est. group size
—
Recurring co-author estimate
Active years
43
Publishing since 1981
Publication cadence
Publications per year over the last 10 years — averaging 4.0/year recently
Recent publications
- Supplementary figure 3 from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Supplementary figure 3 from Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
2023
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
2023
- Figures 1-3 from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
2023
- Supplementary Table 1 from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
2023
- Figures 1-3 from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
2023
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
2023
- Vitamin D and Paget's disease
Elsevier eBooks · 2023
- Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation
JCI Insight · 2023
- Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
Haematologica · 2023
- The acid-sensing nociceptor TRPV1 controls breast cancer progression in bone via regulating HGF secretion from sensory neurons
Research Square · 2023
- Supplementary Figure S1 from Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3
2023
- Supplementary Figure S2 from Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3
2023
- Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
2023
- Data from Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
2023
Publishes in
- Blood×19
- Elsevier eBooks×7
- Cancer Research×5
- PMC×5
- Journal of bone oncology×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile